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Abstract 13 
Simplified monomeric monoclonal antibodies consisting of a single-domain VHH, derived 14 
from camelid heavy-chain only antibodies, fused with the Fc domain of either IgG (VHH-IgG) 15 
or IgA (VHH-IgA) antibodies, are promising therapeutic proteins. These simplified single-gene 16 
encoded antibodies are much easier to manufacture and for bulk applications can be produced 17 
in plants and in yeast. These merits enabling novel passive immunization applications, such as 18 
in-feed oral delivery of VHH-IgA, which successfully protected against a gastrointestinal 19 
infection in piglet model. 20 
Introduction 21 
For over a century, passive immunization is known as the answer to infections when no drugs 22 
or vaccines are available. In this procedure, convalescent immune sera from individuals 23 
recovered from infections are transfused into infected persons to provide immediate protection. 24 
Also, serum therapy with antitoxins, i.e. antibodies able to neutralize a specific toxin, and 25 
toxoids, i.e. an inactivated toxin with maintained immunogenic properties, produced by actively 26 
immunized horses was used for a long time to treat particular diseases such as diphtheria and 27 
tetanus, and also to neutralize venom toxins after snake bites [1]. The advent of recombinant 28 
DNA techniques has enabled the precise engineering and production of monoclonal antibodies 29 
with higher efficiency and specificity, which also results in less adverse effects. Production of 30 
these conventional mammalian monomeric Y-shaped IgGs (Figure 1a) for intravenous 31 
application is expensive, while that of dimeric secretory IgAs (SIgAs), which may be applied 32 
topically at mucosal surfaces, is highly challenging (Figure 1b).  33 
To produce an IgG, the transgenic cells should carry the genes encoding the heavy and light 34 
chains, both of which should be expressed to yield high quantities of assembled active IgG 35 
antibodies. The production of SIgAs is even more complex, because they require four different 36 
genes. Next to the genes coding for the heavy and light IgA chains in the monomeric IgA 37 
(Figure 1c), the genes encoding the J chain and the secretory component should also be present, 38 
such that two monomeric IgAs can be assembled by the J chain and secretory component into 39 
a single active SIgA (Figure 1b).  40 
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How to simplify the production of IgG and SIgA antibodies? 41 
One way to simplify the production of IgGs and SIgAs is to reduce the number of genes 42 
required. This can be achieved by connecting the variable domain of the light chain and the 43 
heavy chain via a flexible linker in a single reading frame, which is called a single-chain 44 
variable fragment (scFv). Although scFv and scFv-fusion antibody drugs are available on the 45 
market or under clinical investigation [2,3], designing of the linker is crucial in obtaining active  46 
scFvs, which remains tedious and an empirical process. The success depends on the precise 47 
stoichiometric pairing of the variable domains, which is governed by the flexibility and length 48 
of the empirically designed linker. An effective alternative is to replace the antigen-binding Fab 49 
fragment by a single-domain VHH or nanobody derived from heavy-chain only antibodies 50 
(Figure 1d) found in camelids [4]. The VHHs are more compact and small (~15 kDa) with a 51 
stable immunoglobulin fold, making them more robust than scFvs [5]. Furthermore, the 52 
structural properties of VHHs most often enable the targeting of epitopes inaccessible to 53 
conventional antibodies (e.g. deep enzyme clefts), which broadens the range for finding 54 
neutralizing epitopes. Also, because all epitope binding information is conferred to a stable 55 
single domain, fusing these VHHs genetically to other proteins is much easier than scFvs. For 56 
instance, the VHHs can be fused to a fluorescent protein such as GFP, making them interesting 57 
new tools to study and visualize the VHH targets in in vivo intracellular localization studies [6].  58 
To obtain simplified VHH-Fc antibodies, the VHH of interest is grafted on the Fc domain of an 59 
IgG (VHH-IgG) or and IgA (VHH-IgA) at the hinge region [7] (Figure 2b). This results in 60 
bivalent monomeric VHH-Fc fusions that can easily be produced in different platforms, as they 61 
are encoded by only a single gene and have been demonstrated to express at high levels in plant 62 
seeds (e.g. Arabidopsis and soybean) and yeast (Pichia pastoris). Moreover, the VHH-Fc 63 
fusions gain the particular properties of the Fc region, such as increased half-life and effector 64 
functions. 65 
To obtain simplified SIgA antibodies (sSIgAs), the J chain and secretory component have to be 66 
co-expressed with the VHH-IgA molecule [7-9]. Several methods could be used for introducing 67 
the three genes in the same cell, such as simultaneous introduction - as a tandem construct or 68 
triple co-transformation, or rather successive introduction - either by successive super-69 
transformation or genetic crossing. In dicot seeds, the highest level of sSIgA expression has 70 
been obtained by first identifying transformants expressing high amounts of both the J chain 71 
and the secretory component, and super-transforming or crossing them with plants expressing 72 
the bivalent monomeric VHH-IgA molecule [8]. Indeed, expression of several genes in the 73 
same plant cell, even if the same promoter is used, does not necessarily result in the same 74 
amounts of transcripts or co-translated constituent protein chains of the sSIgA. Such 75 
discrepancy in proportions often results in heterogenous mix, i.e. along with the fully assembled 76 
sSIgAs, partially covalently linked assemblies such as bivalent monomeric VHH-IgAs (Figure 77 
2a) without J chain or secretory component (Figure 2d), or tetravalent VHH-IgAs with J chain 78 
and without secretory component (dimeric VHH-IgA, Figure 2c), possibly together with free J 79 
chain and free secretory component [7]. Future efforts in improving production yield will have 80 
to enable a higher ratio of assembled sSIgAs over other undesired partial assemblies [7]. 81 
However, it should be noted that even partially assembled sSIgAs in the heterogenous mixture 82 
can be efficacious [7,10]. Hence, for most mucosal applications e.g. enteric antibacterial 83 
antibodies in gut lumen, a heterogenous mix of VHH-IgA-based antibody formats may not be 84 
a drawback [7].   85 
Applications of VHH-IgG antibody fusions 86 
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Quite some VHH-IgGs are being explored for new applications and characteristics. For passive 87 
immunization against bacteria and viruses, VHHs and derived fusions are being tested for their 88 
neutralization efficacy. A recent example highlights the innovative potential of modular VHH 89 
fusions, where four different VHHs, each recognizing a different epitope of diverged influenza 90 
hemagglutinin molecules, resulting in a tetramer that binds and neutralizes a broad range of 91 
influenza A and B viruses. Fusing this VHH tetramer with the Fc of human IgG1 (multidomain 92 
VHH-IgG, schematically represented in Figure 2e) resulted in a strongly increased potency and 93 
breadth of influenza neutralization [11••]. 94 
Also, in cancer, VHH-IgGs are further explored. A VHH binding to nucleolin and fused to the 95 
Fc of IgG1 showed increased binding, antiproliferative effects and cytotoxicity against cancer 96 
cells compared to the corresponding VHH by itself [12•]. 97 
Further, progress is promised in the field of toxin neutralization. While VHHs binding 98 
Clostridium difficile toxin B with high affinity could not neutralize the toxin, VHH-IgG fusions 99 
reached toxin neutralization comparable to the FDA-approved anti-toxin B monoclonal 100 
antibody [13]. Similarly, fusion of VHHs binding botulinum neurotoxin A with an Fc of IgG1 101 
significantly increased the circulation time in the blood and provided a much higher efficacy 102 
than the VHHs they were derived from [14]. 103 
The use of VHH-IgGs has also been evaluated to prolong the passive immunization and 104 
protection of newborn piglets provided by the antibodies in the colostrum and mother milk 105 
against F4-producing enterotoxigenic Escherichia coli (F4-ETEC). By fusing VHHs binding 106 
the subunit of the F4 fimbriae of the pathogenic bacteria to the Fc of porcine IgG antibodies, 107 
monomeric F4-specific VHH-IgGs were obtained [7]. Adding these VHH-IgG antibodies to 108 
F4-ETEC bacteria resulted in aggregation and large clumps of the F4-carrying bacteria, and 109 
also inhibited the attachment of the F4-ETEC to gut villous enterocytes in vitro [7]. It was thus 110 
predicted that these VHH-IgG antibodies would also prevent colonization of F4-ETEC in the 111 
gut, but surprisingly oral consumption of these VHH-IgGs did not, whereas the corresponding 112 
F4-specific SIgAs did protect against an F4-ETEC challenge, demonstrating that the choice of 113 
Fc fragment is crucial in its efficacy [7] (see below). 114 
Applications of SIgAs and derived VHH-IgA antibody fusions 115 
There are less examples of SIgA-based approaches for passive immunization, although this 116 
seems the way to go for pathogen neutralization at the mucosal surfaces. The main reason for 117 
this is the difficulty in manufacturing of SIgA antibodies. However, several experiments 118 
showing SIgA-mediated passive immunization warrant further investigation. For example, 119 
specific SIgA antibodies were shown to enchain growing Salmonella bacteria in cloned clusters 120 
and to prevent conjugation of drug resistance-carrying plasmids among different strains [15••]. 121 
Also, piglets fed with the simplified anti-F4 sSIgA antibodies were protected against F4-ETEC 122 
colonization after a challenge with F4-ETEC [7]. Furthermore, Virdi et al. recently showed that 123 
the single-gene encoded monomeric anti-F4 VHH-IgAs are also efficacious in protecting 124 
piglets against F4-ETEC challenge, not requiring the assembled sSIgA format [16••]. Why 125 
these monomeric VHH-IgAs did provide in vivo protection, in contrast to the monomeric VHH-126 
IgGs, remains an open question. Better stability and higher retention at the gut mucosa may be 127 
the plausible reasons for the edible VHH-IgA’s efficacy.  128 
How general is the VHH-IgA antibody approach? 129 
The single-gene encoded monomeric VHH-IgA format has been proven to be efficient for gut 130 
mucosal protection in the porcine model [7,16••]. Being a highly related model for the human 131 
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gut, this is likely to encourage and boost research for prophylactic and therapeutic use of this 132 
type of VHH-IgA antibodies. Such future body of research against a variety of mucosal targets 133 
will unravel how general the VHH-IgA approach can be. Below are the latest applications 134 
exploring VHH-IgA-based approaches. 135 
Enterohemorrhagic E. coli (EHEC) is a foodborne pathogen that colonizes the bovine 136 
gastrointestinal tract. Saberianfar et al. describe the isolation of a VHH specific for the intimin 137 
adhesin that is involved in the colonization and its fusion with the Fc domain of IgA [17•]. 138 
Transgenic Nicotiana benthamiana plants carrying this VHH-IgA, the J chain and the secretory 139 
component, produced and assembled secretory VHH-IgA antibodies in their leaves, of which 140 
one (VHH10-IgA) bound to the most prevalent EHEC serotypes and neutralized the adhesion 141 
to epithelial cells in vitro [17•]. 142 
Another recent publication describes the fusion of VHHs directed against the Campylobacter 143 
flagella and major outer membrane proteins, to the constant domain of chicken IgA [18•]. 144 
Campylobacter jejuni causes a zoonotic infectious disease in humans, leading to major health 145 
problems; chickens are considered as the main reservoir. The designer chimeric antibodies were 146 
effectively produced in N. benthamiana leaves and Arabidopsis thaliana seeds, and they did 147 
not only bind to their purified antigens but also to Campylobacter bacterial cells. In addition, 148 
the anti-flagellin chimeric antibodies reduced the motility of Campylobacter bacteria in vitro. 149 
Both studies showed a strong effect of the VHH-IgAs in vitro, but it is now crucial to also test 150 
the effect of the anti-EHEC and anti-Campylobacter VHH-IgAs in vivo in the target host.    151 
Plant seeds and yeast as scalable production platforms for VHH-Fc antibodies  152 
Many VHH-Fc applications are possible, and the results of some case studies are promising. In 153 
this respect, two different systems should be considered: on the one hand the parenteral 154 
administration of antibodies and on the other hand the topical, mucosal and diagnostic use of 155 
antibodies. Currently, the most frequent use of antibodies is the parenteral application of 156 
conventional IgGs administered as injectables. These therapeutic IgGs need to be highly 157 
purified and the quality strictly controlled and regulated. Also, the post-translational 158 
modifications, of which especially glycosylation pattern, is very important to be characterized 159 
to minimize adverse reactions. Therefore, it is logical that IgG monoclonal antibody production 160 
is largely confined to mammalian cell expression systems, which are well characterized and 161 
deregulated. In this respect, alternative production platforms such as yeast and plant systems 162 
are not favored at this time because of their different glycoforms. However, glycoengineering 163 
of the yeast and plant cell systems might make these platforms competitive in the future, over 164 
mammalian cell culture-based secreted antibodies that require big investments and rely on 165 
expensive media and production processes [19]. The high cost of the mammalian production 166 
platforms may drive the production of a range of new VHH-IgG based injectables towards well 167 
controlled plant and yeast systems.  168 
However, the situation is completely different when the antibodies are used for mucosal or 169 
topical administration or for the use in diagnostics for specific infections or allergens. Then 170 
different glycoforms are not an issue, and more scalable and cost-effective platform exploration 171 
is an important asset. Especially for oral passive immunization, which would require milligram 172 
to gram quantities of antibodies per treated individual over days to few weeks. This is much 173 
higher than in case of indications addressed by intravenous antibodies that typically have higher 174 
circulatory half-life of a several days in the blood. Fulfilling this high demand in a cost-effective 175 
way with current mammalian cell-based manufacturing would be a big challenge. Moreover, 176 
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for mucosal passive immunization the production of SIgAs in mammalian cells gives very low 177 
yields and is therefore not feasible. Thus, for many new applications scalable production 178 
platforms will be needed, where plant and yeast expression systems are getting due attention 179 
[20,21].  180 
Here, we specifically focus on the use of the plant seeds and on P. pastoris cultures as 181 
production platforms, because the simplified VHH-IgG and VHH-IgA antibodies produced in 182 
these systems do not need to be purified for oral applications; moreover, they are scalable and 183 
cheap. In addition, unlike mammalian expression systems, they do not harbor the potential risk 184 
of human-specific virus contamination [22].  185 
De Meyer et al. compared the production of several VHH-IgG fusions in stably transformed 186 
Arabidopsis seeds, in transiently expressing N. benthamiana leaves and in P. pastoris cultures 187 
[23]. Importantly, the VHH-IgGs were equally and successfully produced as bivalent 188 
monomeric functional entities in the three platforms. The main advantage of the transient 189 
expression in N. benthamiana and production in P. pastoris cultures is the speed by which the 190 
antibodies can be obtained, and thus these are interesting platforms in an initial stage of 191 
experimentation [24]. However, the plant seed platform has the advantage that once the seed 192 
stocks are established, they can be stored at ambient temperature for years while the resident 193 
antibodies remain stable and functional [16••]. Seeds are also beneficial platform when large 194 
amounts of antibodies are needed for oral applications [25]. Moreover, seeds allow to uncouple 195 
the production phase and purification phase. Thus, only when the antibodies are needed, for 196 
instance to treat an infectious outbreak, they would have to be extracted from the stockpiled 197 
seed stocks. 198 
Expression levels of VHH-IgGs in seeds of the model plant Arabidopsis were up till 1% of seed 199 
weight and several of the sSIgAs accumulated to about 0.2% of seed weight, of which 50% was 200 
assembled with the J chain and secretory component [7,8,16••]. Accumulation of several 201 
simplified VHH-IgA antibodies in soybean seeds was found to be 0.2% of the seed weight, as 202 
high as in Arabidopsis seeds [8,16••]. Moreover, and importantly, the soybean-produced 203 
unpurified monomeric VHH-IgAs were as protective in an in vivo challenge experiment as the 204 
Arabidopsis seed-produced antibodies [16••]. These results allude to the potential of producing 205 
tons of soybeans containing kilograms of therapeutic antibodies for oral treatment of 206 
gastrointestinal infections not only in animals but also in humans. 207 
Also, tobacco seeds are very efficient in assembling functional antibodies and they are 208 
amenable to upscaling [26]. Tobacco seeds, unlike tobacco leaves, do not contain high levels 209 
of alkaloids. Additionally, since tobacco is not a food crop it is highly unlikely to accidently 210 
contaminate the food chain. 211 
Last but not least, we want to highlight the use of P. pastoris as alternative for the production 212 
of cost-effective large amounts of VHH-Fc antibodies. The recent finding that the medium of 213 
P. pastoris cultures secreting monomeric VHH-IgAs could be spray-dried (a cheap processing 214 
technique of liquids with active components) without losing functionality, is a breakthrough for 215 
VHH-Fc product valorization. Not only can the spray-dried powder be stored as such, but it can 216 
also be admixed in the feed or food when needed. This is expected to open many new 217 
opportunities and applications.  218 
Concluding remarks 219 
Formatting VHHs by fusing them to the Fc domain of conventional IgG or IgA antibodies has 220 
become a commonly applied approach nowadays. These fusions can be used for passive 221 
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immunization against infections and toxin neutralization, and also to prevent a gastrointestinal 222 
infection upon oral administration. These single gene encoded monomeric antibodies, easily 223 
and cost effectively produced in the scalable platforms such as yeast and soybean seeds, opens 224 
new avenues to prevent or treat bacterial and viral infections at mucosal surfaces. Glycosylation 225 
is an important issue to consider for many antibodies based injectable passive immunization 226 
applications, but in several others like oral and topical route heterologous glycans may be of 227 
less concern, especially in such routes exploring the scalable manufacturing capabilities of plant 228 
and yeast expression system is a strong benefit.  229 
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Figure 1. Conventional IgG and IgA antibodies, and the Camelidae heavy-chain only 373 
antibodies. 374 
(a) Conventional mammalian monomeric IgG antibodies are Y-shaped molecules that consist 375 
of two identical heavy and two identical light chains connected by disulfide bonds. The arms 376 
of the Y form the Fab (Fragment, antigen-binding) domain, which binds to the antigen and is 377 
composed of one constant and one variable domain from each heavy and light chain. The base 378 
of the Y is called Fc (Fragment, crystallizable) and is composed of two constant domains from 379 
the heavy chains. (b-c) Mammalian secretory IgA antibodies (b) are a dimer consisting of two 380 
Y-shaped IgA monomers (c) covalently joined by the J chain (purple rectangle) via disulfide 381 
bonds (black lines) and wrapped by the secretory component. (d) In camelids, next to 382 
conventional IgG antibodies, also heavy-chain only IgG antibodies are produced. VL: variable 383 
domain of light chain; CL: constant domain of light chain; VH: variable domain of heavy chain; 384 
VHH: single-domain antigen-binding domain; Cα1, Cα2, Cα3: constant domains of alpha 385 
heavy chain (IgA); Cγ1, Cγ2, Cγ3 constant domains of gamma heavy chain (IgG). 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
Figure 2. Schematic representation of the simplified VHH-Fc fusion antibodies. 403 
(a-b) Monomeric VHH-Fc fusions consisting of VHHs grafted on to the flexible hinge of the 404 
Fc domain derived from either IgA (VHH-IgA, a) or IgG (VHH-IgG, b). (c) Two monomeric 405 
VHH-IgAs bind tail-to-tail via incorporation of the J chain (purple rectangle), and form a 406 
tetravalent (four VHHs) dimeric IgA. (d) The association of the secretory component (blue 407 
band) with the dimeric IgA results in the formation of a secretory VHH-IgA. (e) Four VHHs 408 
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specific for different epitopes can be fused together via a flexible linker and grafted on to a Fc 409 
domain of IgG to form a multispecific/multidomain VHH-IgG. VHH: single-domain antigen-410 
binding domain of camelid heavy-chain only antibody; Cα2, Cα3, Cγ2, Cγ3: constant domains 411 
of heavy chain. 412 
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Rebuttal to the reviewer comments 
 
We would like to take the opportunity to thank the reviewers for their insightful and constructive 
comments. We have revised the manuscript guided by these comments and believe this further improves 
the article. We have highlighted the key changed in red font. 
 
Thank you. 
 
Ann Depicker 
Henri De Greve 
Vikram Virdi 
Shruti Bakshi 
 
 
Our point-by-point reply to each comment is as below.  
 
Reviewer comments: 
 
Reviewer 1 
I read with interest the manuscript by De Greve, et al. I found it to be informative and concise and as such 
appropriate for publication. I recommend accepting the manuscript after minor revisions as follows: 
 
1.    The manuscript will benefit from English language editing. In general use of language is fine; however, 
there are a number of grammatical and other linguistic errors that need to be corrected. 
 
Reply: We thank the reviewer for the appreciation of the manuscript. As requested by the reviewer, we 
have corrected the grammatical and linguistic errors in the revised manuscript. 
 
2.    It would have been helpful to have page and/or line numbers, as this would have facilitated the review 
process.  
 
Reply: Thank you for this remark. We have added the line numbers now. 
 
3.    Abstract: "..: IgG or IgA antibodies are new promising therapeutic proteins". Are they really new? When 
was the first example in the clinic?   
 
Reply: To clarify this further, we have modified the abstract as follows- (Line 15-20) 
 
“Simplified monomeric monoclonal antibodies consisting of a single-domain VHH, derived from camelid 
heavy-chain only antibodies, fused with the Fc domain of either IgG (VHH-IgG) or IgA (VHH-IgA) antibodies, 
are promising therapeutic proteins. These simplified single-gene encoded antibodies are much easier to 
manufacture and for bulk applications can be produced in plants and in yeast. These merits enabling novel 
passive immunization applications, such as in-feed oral delivery of VHH-IgA, which successfully protected 
against a gastrointestinal infection in piglet model.” 
  
4.    A number of terms may not be familiar to non-experts, e.g. antitoxins, toxoids, etc. 
Response to Reviewers
 2 
 
Reply: Thank you for this remark. We have clarified these terms in the revised manuscript. (Line 25) 
 
“Also, serum therapy with antitoxins, i.e. antibodies able to neutralize a specific toxin, and toxoids, i.e. an 
inactivated toxin with maintained immunogenicity properties, produced by actively immunized horses 
…...” 
 
5.    Page 1. Last paragraph. Is it really the case that the heavy and light chains need to be expressed at 
the same levels, etc., etc? I am aware of many examples where efficacy is not influenced by unequal 
production of the two chains. A number of examples in the literature show that excess of one chain does 
not negatively influence performance.  
 
Reply: We agree with the reviewer. To clarify this further, we have modified the text in the revised 
manuscript. (Line 35) 
 
“ To produce an IgG, the transgenic cells should carry the genes encoding the heavy and light chains, both 
of which should be expressed to yield high quantities of assembled active IgG antibodies. The production 
of SIgAs is even more complex, because they require four different genes. Next to the genes coding for 
the heavy and light IgA chains in the monomeric IgA (Figure 1c), the genes encoding the J chain and the 
secretory component should also be present, such that two monomeric IgAs can be assembled by the J 
chain and secretory component into a single active SIgA (Figure 1b). “ 
 
6.    Page 2. Statement in the penultimate sentence will benefit from a reference.  
 
Reply: We have added the following references and also further clarify the statement as below.  
 Virdi et al. [7], Bakshi et al., 2019 [10] (Line 83) 
 
“Hence, for most mucosal applications e.g. enteric antibacterial antibodies in gut lumen, a heterogenous 
mix of VHH-IgA-based antibody formats may not be a drawback. “ 
 
7.    Page 4. "Fulfilling this high demand…with mammalian cell-based… is highly questionable" And yet this 
is the technology currently used commercially! I agree with the authors but a reference or two perhaps 
might strengthen this position.  
 
Reply: Thank you for this comment. We realize is crucial to clarify this point and hence have modified the 
first two paragraphs of this section as follows. (Line 154-182) 
 
Many VHH-Fc applications are possible, and the results of some case studies are promising. In this respect, 
two different systems should be considered: on the one hand the parenteral administration of antibodies 
and on the other hand the topical, mucosal and diagnostic use of antibodies. Currently, the most frequent 
use of antibodies is the parenteral application of conventional IgGs administered as injectables. These 
therapeutic IgGs need to be highly purified and the quality strictly controlled and regulated. Also, the post-
translational modifications, of which especially glycosylation pattern, is very important to be 
characterized to minimize adverse reactions. Therefore, it is logical that IgG monoclonal antibody 
production is largely confined to mammalian cell expression systems, which are well characterized and 
deregulated. In this respect, alternative production platforms such as yeast and plant systems are not 
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favored at this time because of their different glycoforms. However, glycoengineering of the yeast and 
plant cell systems might make these platforms competitive in the future, over mammalian cell culture-
based secreted antibodies that require big investments and rely on expensive media and production 
processes [19]. The high cost of the mammalian production platforms may drive the production of a range 
of new VHH-IgG based injectables towards well controlled plant and yeast systems.  
However, the situation is completely different when the antibodies are used for mucosal or topical 
administration or for the use in diagnostics for specific infections or allergens. Then different glycoforms 
are not an issue, and more scalable and cost-effective platform exploration is an important asset. 
Especially for oral passive immunization, which would require milligram to gram quantities of antibodies 
per treated individual over days to few weeks. This is much higher than in case of indications addressed 
by intravenous antibodies that typically have higher circulatory half-life of a several days in the blood. 
Fulfilling this high demand in a cost-effective way with current mammalian cell-based manufacturing 
would be a big challenge.  Moreover, for mucosal passive immunization the production of SIgAs in 
mammalian cells gives very low yields and is therefore not feasible. Thus, for many new applications 
scalable production platforms will be needed, where plant and yeast expression systems are getting due 
attention [20,21].  
 
8.    Page 5. Reference [18] is hardly an authoritative reference on the topic, the authors can do much 
better! 
 
Reply: Thank you for this suggestion, as you will see in point 7, the paragraph has been modified and 
references [20,21] now replace the previous reference [18]. (Line 180) 
 
9.    Page 5. GRAS status. This is only a recommendation by the US FDA. It makes no difference in other 
jurisdictions, e.g. Europe!  
 
Reply: Thank you for this remark. We have modified the text as follows (Line 184) and added reference 
[22] 
 
“Here, we specifically focus on the use of the plant seeds and on P. pastoris cultures as production 
platforms, because the simplified VHH-IgG and VHH-IgA antibodies produced in these systems do not 
need to be purified for oral applications; moreover, they are scalable and cheap. In addition, unlike 
mammalian expression systems, they do not harbor the potential risk of human-specific virus 
contamination [22].” 
 
Reviewer 2 
 
In this review an analysis on the potential of VHH antibodies fused to IgG/IgA Fc regions is presented, 
highlighting cases based on the use of plants and yeast as the expression host. In my opinion the 
manuscript has a proper structure and described the technology properly. 
 
However, some aspect require attention: 
 
10.     The authors should consider to mention -plants and yeast- in the title as these are the hosts in which 
the review is focused on. 
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Reply: We thank the reviewer for the positive remarks on the manuscript structure and the description.  
We acknowledge your advice, but with this article we intent to spotlight the VHH-Fc antibody format, to 
usher and steer exploration of VHH-based multivalent antibody formats. The simplicity of expressing 
single gene VHH-Fc would provide convenience in any expression platform (mammalian, plant or yeast).  
Every platform would have its due merits depending on the application, and when it comes to antibody 
applications requiring milligram to grams quantity per individual, yeast and plants may be a good 
alternative to consider.  
Acknowledging your comment, we have clarified this not only in the abstract but in entire manuscript. 
And for brevity we even removed the work ‘recombinant’ from the title further shortening the character 
length. 
 
 
11.     What about glycosylation? This aspect is not discussed and is critical in terms of safety (generation 
of undesired immunogenicity) and for certain applications such as cancer therapy, in which the effector 
properties of the antibody are important and could be affected by the glycosylation patterns. 
 
Reply: We agree with the reviewer. Your comment brought to our attention that the readers will benefit 
from clear distinction of the VHH-Fc antibodies that may be injected from the ones that may be orally or 
topically applied.  The heterologous glycosylations are deemed important for preventing adverse reaction 
when injected, not so when their role is topical at mucosal surface. We clarify these points in lines: Line 
155-175 (Also taking into account comment 7 of reviewer 1). 
  
12.     The authors must enlist much in detail the advantages of the plant- and yeast-based production 
platforms, e.g. by providing specific advantages in terms of cost, scalability and biosafety.  
 
Reply: We have discussed the advantages of the plant- and yeast-based production platforms for VHH-IgA 
production in the revised manuscript (Line 155-175). (please see the text of comment 7 of reviewer 1) 
 
13.     Expression approaches could be also mentioned briefly. Moreover, a comparison of such platforms 
should be provided to contrasts their advantages and limitations. What about the singular glycosylation 
machinery of yeast compared to plants? What about glycoengineering approaches in these organisms? 
 
Reply: We agree with the reviewer that these are very interesting topics. However due to space limitations 
of the manuscript (2000 words) addressing the topic is beyond the scope of this review. However, in this 
revised manuscript we have introduced the readers to how this post-translational modification may play 
a role in VHH-Fc applications, stating our own opinion when it comes to oral/topical mucosal or injectable 
route. Additionally, in Line 166 we also added reference of Van Landuyt et al. 2018, which is a more 
pertinent review on glycosylation and covers the issues in more details.  
 
14.     In the concluding remarks section, the authors should provide a real analysis of the current 
knowledge and provide future directions for the field. what are the challenges in terms of regulatory 
approval? Are there some challenges related to yields? What happens with the glycosylation aspect in 
these antibodies? Remains unexplored? Is it critical? In what other diseases these antibodies could be 
applied? I consider these questions of key relevance to enrich this section. 
 
Reply: Please note there is limit to the concluding remark section. In light of your advice, we have added 
following text in the concluding remarks section (Line 228-231) and where fit, we have attempted to touch 
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these points elsewhere in the manuscript. With no regulatory examples of VHH-IgA (or recombinant IgAs) 
for edible/topical mucosal application the regulatory pathway remains unexplored and at this point of 
time is broadly hypothetical, hence we have chosen not to elaborate on it.  
 
“Glycosylation is an important issue to consider for many antibodies based injectable passive 
immunization applications, but in several others like oral and topical route heterologous glycans may be 
of less concern, especially in such routes exploring the scalable manufacturing capabilities of plant and 
yeast expression system is a strong benefit.” 
